{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:20:52Z","timestamp":1791807652086,"version":"4.3.4"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bioorg.2023.107071","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T03:27:25Z","timestamp":1704338845000},"page":"107071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease"],"prefix":"10.1016","volume":"143","author":[{"given":"Wanqiu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongcheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixuan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2023.107071_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111616","article-title":"Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism","volume":"549","author":"Zhou","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bioorg.2023.107071_b0010","doi-asserted-by":"crossref","first-page":"e005","DOI":"10.1621\/nrs.08005","article-title":"Deciphering the nuclear bile acid receptor FXR paradigm","volume":"8","author":"Modica","year":"2010","journal-title":"Nucl. Recept. Signal."},{"key":"10.1016\/j.bioorg.2023.107071_b0015","doi-asserted-by":"crossref","first-page":"10918","DOI":"10.1074\/jbc.275.15.10918","article-title":"Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription","volume":"275","author":"Chiang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2023.107071_b0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.apsb.2015.01.005","article-title":"Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration","volume":"5","author":"Li","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2023.107071_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166133","article-title":"FXR in liver physiology: Multiple faces to regulate liver metabolism","volume":"1867","author":"Panzitt","year":"2021","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.bioorg.2023.107071_b0030","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1152\/physrev.00027.2002","article-title":"Bile salt transporters: molecular characterization, function, and regulation","volume":"83","author":"Trauner","year":"2003","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bioorg.2023.107071_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107542","article-title":"Novel insights into the organic solute transporter alpha\/beta, OST\u03b1\/\u03b2: From the bench to the bedside","volume":"211","author":"Beaudoin","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2023.107071_b0040","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/gast.2001.25503","article-title":"The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp","volume":"121","author":"Denson","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bioorg.2023.107071_b0045","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12072-010-9202-6","article-title":"Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease","volume":"4","author":"Yang","year":"2010","journal-title":"Hepatol Int"},{"key":"10.1016\/j.bioorg.2023.107071_b0050","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bioorg.2023.107071_b0055","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbalip.2014.03.013","article-title":"Physiological regulation of lipoprotein lipase","volume":"1841","author":"Kersten","year":"2014","journal-title":"Biochim Biophys Acta Bioenerg"},{"key":"10.1016\/j.bioorg.2023.107071_b0060","doi-asserted-by":"crossref","first-page":"e027958","DOI":"10.1161\/JAHA.122.027958","article-title":"Flow-Induced Secretion of Endothelial Heparanase Regulates Cardiac Lipoprotein Lipase and Changes Following Diabetes","volume":"11","author":"Lee","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.bioorg.2023.107071_b0065","article-title":"Miniseries: Established pharmacological targets for NASHFXR agonists in NASH treatment","author":"Adorini","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2023.107071_b0070","first-page":"12","article-title":"Emerging role of nuclear receptors for the treatment of NAFLD and NASH","author":"Welch","year":"2022","journal-title":"Metabolites."},{"key":"10.1016\/j.bioorg.2023.107071_b0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastro Hepat."},{"key":"10.1016\/j.bioorg.2023.107071_b0080","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s42000-022-00391-w","article-title":"Detangling the interrelations between MAFLD, insulin resistance, and key hormones","volume":"21","author":"Pal","year":"2022","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.bioorg.2023.107071_b0085","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2023.107071_b0090","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet. Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.bioorg.2023.107071_b0095","doi-asserted-by":"crossref","first-page":"245","DOI":"10.7861\/clinmedicine.18-3-245","article-title":"Non-alcoholic fatty liver disease","volume":"18","author":"Maurice","year":"2018","journal-title":"Clin. Med. (London, England)"},{"key":"10.1016\/j.bioorg.2023.107071_b0100","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2023.107071_b0105","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2741\/4892","article-title":"Current treatment paradigms and emerging therapies for NAFLD\/NASH","volume":"26","author":"Raza","year":"2021","journal-title":"Front. Biosci."},{"key":"10.1016\/j.bioorg.2023.107071_b0110","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/13543776.2018.1459569","article-title":"Farnesoid X receptor modulators 2014-present: a patent review","volume":"28","author":"Sepe","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2023.107071_b0115","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile acid control of metabolism and inflammation in obesity, Type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease","volume":"152","author":"Chavez-Talavera","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bioorg.2023.107071_b0120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14728222.2019.1559825","article-title":"The farnesoid X receptor: a potential target for expanding the therapeutic arsenal against kidney disease","volume":"23","author":"Masaoutis","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bioorg.2023.107071_b0125","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/gut.2010.212159","article-title":"Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease","volume":"60","author":"Gadaleta","year":"2011","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.bioorg.2023.107071_b0130","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41401-022-00880-z","article-title":"Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease","volume":"43","author":"Jiao","year":"2022","journal-title":"Acta Pharmacol. Sin"},{"issue":"4","key":"10.1016\/j.bioorg.2023.107071_b0135","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11883-015-0500-2","article-title":"FXR agonists as therapeutic agents for non-alcoholic fatty liverdisease","volume":"17","author":"Carr","year":"2015","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"10.1016\/j.bioorg.2023.107071_b0140","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1042\/BST20210658","article-title":"Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders","volume":"50","author":"Molinaro","year":"2022","journal-title":"Biochem. Soc. Trans."},{"issue":"1","key":"10.1016\/j.bioorg.2023.107071_b0145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00108-017-0347-4","article-title":"Modern treatment of primary biliary cholangitis","volume":"59","author":"Strassburg","year":"2018","journal-title":"Der Internist"},{"issue":"1","key":"10.1016\/j.bioorg.2023.107071_b0150","first-page":"5","article-title":"Recent advances in the development of farnesoid X receptor agonists","volume":"3","author":"Ali","year":"2015","journal-title":"Ann. Transl. Med."},{"issue":"9972","key":"10.1016\/j.bioorg.2023.107071_b0155","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bioorg.2023.107071_b0160","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"The diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"EASL Clinical Practice Guidelines","year":"2017","journal-title":"J. Hepatol"},{"issue":"16","key":"10.1016\/j.bioorg.2023.107071_b0165","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1021\/jm0002127","article-title":"Identification of a chemical tool for the orphan nuclear receptor FXR","volume":"43","author":"Maloney","year":"2000","journal-title":"J. Med. Chem"},{"issue":"1","key":"10.1016\/j.bioorg.2023.107071_b0170","doi-asserted-by":"crossref","first-page":"18873","DOI":"10.1038\/s41598-022-23539-5","article-title":"Effect of FXR agonist GW4064 in the treatment of hilar cholangiocarcinoma in rats","volume":"12","author":"Wang","year":"2022","journal-title":"Sci. Rep"},{"issue":"8","key":"10.1016\/j.bioorg.2023.107071_b0175","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep4.1368","article-title":"Tropifexor-mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents","volume":"3","author":"Hernandez","year":"2019","journal-title":"Hepatol. Commun."},{"issue":"3","key":"10.1016\/j.bioorg.2023.107071_b0180","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpdd.762","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel non-bile acid FXR agonist tropifexor (LJN452) in healthy volunteers","volume":"9","author":"Badman","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev"},{"issue":"1","key":"10.1016\/j.bioorg.2023.107071_b0185","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: A Phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2023.107071_b0190","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2023.107071_b0195","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2023.107071_b0200","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/cpdd.960","article-title":"Safety, pharmacokinetics, pharmacodynamics, and formulation of liver-distributed farnesoid X-receptor agonist TERN-101 in healthy volunteers","volume":"10","author":"Wang","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.bioorg.2023.107071_b0205","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.107071_b0210","unstructured":"Safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with NASH; Clinical Trials.gov Identifier: NCT02913105."},{"key":"10.1016\/j.bioorg.2023.107071_b0215","doi-asserted-by":"crossref","first-page":"8948","DOI":"10.1021\/acs.jmedchem.2c00165","article-title":"Discovery of BMS-986339, a pharmacologically differentiated farnesoid X receptor agonist for the treatment of nonalcoholic steatohepatitis","volume":"65","author":"Nara","year":"2022","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2023.107071_b0220","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.bioorg.2023.107071_b0225","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1097-2765(03)00104-7","article-title":"A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR","volume":"11","author":"Downes","year":"2003","journal-title":"Mol. Cell"},{"issue":"15","key":"10.1016\/j.bioorg.2023.107071_b0230","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1016\/j.bmcl.2017.06.003","article-title":"A novel intestinal-restricted FXR agonist","volume":"27","author":"Wang","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"5","key":"10.1016\/j.bioorg.2023.107071_b0235","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep4.1054","article-title":"Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease","volume":"1","author":"Younossi","year":"2017","journal-title":"Hepatol. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2023.107071_b0240","doi-asserted-by":"crossref","first-page":"E625","DOI":"10.1016\/S0618-8278(19)31571-3","article-title":"SAT-341-MET409, an optimized sustained FXR agonist, was safe and well-tolerated in a 14-day phase 1 study in healthy subjects","volume":"70","author":"Chen","year":"2019","journal-title":"J. Hepatol"},{"issue":"1","key":"10.1016\/j.bioorg.2023.107071_b0245","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol"},{"issue":"9","key":"10.1016\/j.bioorg.2023.107071_b0250","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1021\/acs.jmedchem.2c01918","article-title":"Discovery of the first-in-class intestinal restricted FXR and FABP1 dual modulator ZLY28 for the treatment of nonalcoholic fatty liver disease","volume":"66","author":"Ren","year":"2023","journal-title":"J. Med. Chem."},{"issue":"4, Supplement 1","key":"10.1016\/j.bioorg.2023.107071_b0255","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1016\/S0016-5085(16)30669-2","article-title":"825 BAR502, a Dual FXR and GPBAR1 agonist, reverses steatosis and fibrosis in rodent model of NASH By modulating authophagic genes","volume":"150","author":"Renga","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bioorg.2023.107071_b0260","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41598-023-28647-4","article-title":"Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH","volume":"13","author":"Marchian\u00f2","year":"2023","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.bioorg.2023.107071_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2022.05.008","article-title":"MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH","volume":"34","author":"Gao","year":"2022","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.bioorg.2023.107071_b0270","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/bcpt.13122","article-title":"Protective effect of isochlorogenic acid B on liver fibrosis in non-alcoholic steatohepatitis of mice","volume":"124","author":"Liu","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2023.107071_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108117","article-title":"The regulatory role and mechanism of autophagy in energy metabolism-related hepatic fibrosis","volume":"234","author":"Hou","year":"2022","journal-title":"Pharmacol. Ther"},{"issue":"1","key":"10.1016\/j.bioorg.2023.107071_b0280","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00441-011-1246-y","article-title":"TGF-\u03b2 in progression of liver disease","volume":"347","author":"Dooley","year":"2012","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.bioorg.2023.107071_b0285","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lfs.2017.11.027","article-title":"Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice","volume":"192","author":"Zhang","year":"2018","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2023.107071_b0290","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.27332","article-title":"Hepatic inflammation and fibrosis: functional links and key pathways","volume":"61","author":"Seki","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2023.107071_b0295","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ejphar.2015.05.005","article-title":"Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet","volume":"761","author":"Ding","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bioorg.2023.107071_b0300","first-page":"275","article-title":"Gene expression profiling reveals a diverse array of pathways inhibited by nuclear receptor SHP during adipogenesis","volume":"2","author":"Song","year":"2009","journal-title":"Int. J. Clin. Exp. Patho."},{"issue":"1","key":"10.1016\/j.bioorg.2023.107071_b0305","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/hep.32221","article-title":"Breviscapine alleviates NASH by inhibiting TGF-\u03b2-activated kinase 1-dependent signaling","volume":"76","author":"Lan","year":"2022","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bioorg.2023.107071_b0310","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.ymthe.2022.02.021","article-title":"Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma","volume":"30","author":"Yang","year":"2022","journal-title":"Mol. Ther"},{"key":"10.1016\/j.bioorg.2023.107071_b0315","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.744483","article-title":"viaMicronized palmitoylethanolamide ameliorates methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis inhibiting inflammation and restoring autophagy","volume":"12","author":"Hu","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.bioorg.2023.107071_b0320","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J. Hepatol"},{"issue":"3","key":"10.1016\/j.bioorg.2023.107071_b0325","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.bioorg.2023.107071_b0330","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/hep.32475","article-title":"Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score","volume":"76","author":"Pai","year":"2022","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bioorg.2023.107071_b0335","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1891\/NN-2021-0003","article-title":"The eat, sleep, console method: A literature review","volume":"41","author":"Nicholson","year":"2022","journal-title":"Neonatal Network: NN"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823007320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823007320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:04:55Z","timestamp":1758618295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206823007320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":67,"alternative-id":["S0045206823007320"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.107071","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.107071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107071"}}